Analog Devices, Inc. (NASDAQ: ADI) today announced the appointment of Andrea F. Wainer, a seasoned healthcare executive, to its Board of Directors as an independent director. She will also serve as a member of the Board’s Nominating and Corporate Governance Committee.
“We are delighted to welcome Andrea to the ADI Board, as her deep experience and leadership in the healthcare sector will provide ADI with an important source of wisdom and knowledge as we navigate the rich opportunity landscape ahead of us,” said Vincent Roche, ADI’s CEO and Chair.
Wainer is a highly versatile, results-oriented leader with expertise leading innovative businesses at Abbott Laboratories (Abbott), Pfizer and Astellas Pharma. Since 2019, she has served as Executive Vice President, Rapid and Molecular Diagnostics at Abbott. In this role, she leads three businesses – one focused on molecular diagnostics and the analysis of DNA and RNA at the molecular level, the second a provider of rapid point-of-care diagnostics, and the third delivers a leading hand-held point-of-care device.
Previous roles held include President, Abbott Molecular Diagnostics; President, Abbott Animal Health; and Divisional Vice President/General Manager, Abbott Renal Care.
Wainer also serves as a member of the Board of Trustees of the Goodman Theatre.
She earned a Bachelor’s Degree in Accounting from the John M. Olin School of Business, Washington University and a Master’s Degree in Business Administration from the Kellogg School of Management, Northwestern University.
About Analog Devices, Inc.
Analog Devices, Inc. (NASDAQ: ADI)是全球领先的半导体公司，致力于在现实世界与数字世界之间架起桥梁，以实现智能边缘领域的突破性创新。ADI提供结合模拟、数字和软件技术的解决方案，推动数字化工厂、汽车和数字医疗等领域的持续发展，应对气候变化挑战，并建立人与世界万物的可靠互联。ADI公司2024财年收入超过90亿美元，全球员工约2.4万人。ADI助力创新者不断超越一切可能。更多信息，请访问 www.analog.com/cn。
